The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
Open accessAbstract
Targeting Vps34 makes melanoma and CRC eligible to anti–PD-1/PD-L1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse CRC model, the autophagy inhibitors, such as SB02024 and SAR405, increased NK and T cell infiltration in TME and reversed resistance to anti-PD-1 or anti-PD-L1 [47].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Supporting this finding, lysosomotropic agents or small molecules targeting the PtdIns3K PIK3C3/VSP34 have been efficiently combined with therapeutic regimens that promote the activation of the immune system against cancer cells (Janji et al, 2020; Noman et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Noman et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“This statement is supported by clinical data showing that the presence of preexisting T cells close to the invasive tumor margin is a key determinant to achieving a long-lasting response to anti–PD-1 therapy in melanoma (4).”
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 5×
“INTRODUCTION Immune checkpoint inhibitors (ICIs), exemplified by antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), are groundbreaking treatment for many cancers, including melanoma (1).”
InfluentialChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206 · cited 1×
“CCL5, CXCL10, and IFN are all known to promote recruitment of cytotoxic T cells into the TME (18), and this is likely the explanation for why we observed enhanced recruitment of NK, CD8+ T, and CD4+ T effector cells into the tumor bed following Vps34 inhibition.”
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“We used melanoma B16F10, previously described as immune hot tumors but not responding to anti–PD-L1/PD-1 (21), and CRC CT26, reported as immune cold tumors and partially responding to anti–PD-L1/PD-1 (22).”
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498 · cited 1×
“While the impact of blocking autophagy on the inhibition of tumor growth has been well documented by several studies ( 7 , 8 , 14 , 23 – 26 ), the effect of targeting autophagy on the immune landscape of tumors is still only partially defined.”
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In this regard, it is tempting to speculate that type I IFN signature could be responsible for triggering the release of more CCL5 and CXCL10 in the TME, as previously reported (37), to attract more NK and CD8+ T cells into the tumor bed.”
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · cited 1×
“The immune phenotyping of tumors combined with the cytokine network results reported in this study strongly predicts that the immune-supportive characteristic of Vps34itreated TME relies on the establishment of an inflamed TME supported by the presence of tumor-infiltrating lymphocytes, high levels of IFN-producing C…”
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“The majority of patients treated with ICIs as single agents reap limited or no benefits at all (2).”
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
p53 status determines the role of autophagy in pancreatic tumour development
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., et al. (2013) · Nature · doi:10.1038/nature12865 · Cited by 713
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · cited 1×
“We used melanoma B16-F10, previously described as immune hot tumors but not responding to anti–PD-L1/PD-1 ( 21 ), and CRC CT26, reported as immune cold tumors and partially responding to anti–PD-L1/PD-1 ( 22 ).”
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1681 · Cited by 500 · cited 3×
“Two diverse and selective Vps34 kinase inhibitors (Vps34i) were used: SB02024 developed by Sprint Bioscience ( 12 ) and SAR405 developed by Sanofi Pharma ( 11 ).”
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472 · cited 2×
“Durable clinical responses using anti–PD-1/PD-L1–based therapy have been associated with T cell–inflamed tumor microenvironment (TME) favoring the infiltration of functional cytotoxic T lymphocytes (CTLs) (3).”
A dual role for autophagy in a murine model of lung cancer
Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., Sykacek, P., Frank, L., Schramek, D., Komnenovic, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms4056 · Cited by 442
Tumor Vessel Normalization by Chloroquine Independent of Autophagy
Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.025 · Cited by 410 · cited 2×
“However, the role of targeting autophagy on the inhibition of tumor growth and the infiltration of cytotoxic immune cells is well supported by several studies ( 8 , 9 , 14 , 23 – 25 , 27 , 29 ).”
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function
Jaber, N., Dou, Z., Chen, J.-S., Catanzaro, J., Jiang, Y.-P., Ballou, L. M., Selinger, E., Ouyang, X., Lin, R. Z., Zhang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112848109 · Cited by 385 · cited 1×
“Previous studies have found that complete genetic ablation of Vps34 in liver or heart led to the development of hepatomegaly and hepatic steatosis or car-diomegaly and decreased contractility, respectively ( 31 ).”
Autophagy maintains tumour growth through circulating arginine
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0697-7 · Cited by 360 · cited 1×
“7 of 10 mice significantly decreased the tumor growth of YUMM melanoma through the release of Arginase I from the liver, which is responsible for the degradation of Arginine required for the tumor growth (14).”
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351 · cited 14×
“The data presented here provide evidence that the microenvironment of melanoma and CRC tumors treated with Vps34i became highly inflamed compared with that of vehicle-treated tumors.”
InfluentialYang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0952 · Cited by 349
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344 · cited 1×
“We have reported extensive data showing that autophagy activation in tumor cells plays a major role in impairing the antitumor immune response, providing evidence that targeting autophagy inhibits tumor growth and improves CTL and natural killer (NK)–mediated killing (7, 8).”
Self-citationLC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance
Cunha, L. D., Yang, M., Carter, R., Guy, C., Harris, L., Crawford, J. C., Quarato, G., Boada-Romero, E., Kalkavan, H., Johnson, M. D. L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.061 · Cited by 334
Role of autophagy in suppression of inflammation and cancer
White, E., Karp, C., Strohecker, A. M., Guo, Y., & Mathew, R. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.008 · Cited by 328 · cited 1×
“It should be underlined that autophagy was previously described to suppress inflammation (35) and regulate NFB signaling by several mechanisms, including the suppression of inflammasome activation or the degradation of pro-inflammatory signaling factors.”
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Autophagy-Dependent Production of Secreted Factors Facilitates Oncogenic RAS-Driven Invasion
Lock, R., Kenific, C. M., Leidal, A. M., Salas, E., & Debnath, J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0841 · Cited by 281 · cited 1×
“Moreover, it has been shown that autophagy promotes cancer cell invasion by coordinating the production of multiple secreted factors (16).”
Emerging strategies to effectively target autophagy in cancer
Rebecca, V. W., & Amaravadi, R. K. (2016) · Oncogene · doi:10.1038/onc.2015.99 · Cited by 278
Self-citationNoman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256
Self-citationMgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226 · cited 2×
“We have recently reported that genetic targeting of Beclin1 (BECN1) in melanoma cells induced a massive infiltration of NK cells into tumors (9).”
Self-citationInflammatory signaling cascades and autophagy in cancer
Monkkonen, T., & Debnath, J. (2018) · Autophagy · doi:10.1080/15548627.2017.1345412 · Cited by 186 · cited 1×
“Autophagy can elicit both anti- and pro-inflammatory effects in the TME via its cell-specific effects on NFB signaling (36).”
Autophagy Regulation of Metabolism Is Required for CD8+ T Cell Anti-tumor Immunity
DeVorkin, L., Pavey, N., Carleton, G., Comber, A., Ho, C., Lim, J., McNamara, E., Huang, H., Kim, P., Zacharias, L. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.037 · Cited by 185 · cited 1×
“The mechanism underlying this shift seems to be related to an enhanced glucose metabolism (38).”
BackgroundIdentification of secreted proteins that reflect autophagy dynamics within tumor cells
Kraya, A., Piao, S., Xu, X., Zhang, G., Herlyn, M., Gimotty, P. A., Levine, B., Amaravadi, R. K., & Speicher, D. W. (2014) · Autophagy · doi:10.4161/15548627.2014.984273 · Cited by 128
Self-citationDyczynski, M., Yu, Y., Otrocka, M., Parpal, S., Braga, T., Henley, A. B., Zazzi, H., Lerner, M., Wennerberg, K., Viklund, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.028 · Cited by 120 · cited 4×
“Vps34i SB02024 was provided by Sprint Bioscience (Sweden) and administered to the mice at 20 mg/kg by oral gavage.”
InfluentialSelf-citationStarobinets, H., Ye, J., Broz, M. L., Barry, K. C., Goldsmith, J., Marsh, T., Rostker, F., Krummel, M. F., & Debnath, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85705 · Cited by 82 · cited 1×
“A recent study reported that targeting autophagy had no impact neither on tumor growth nor on the infiltration and function of T lymphocytes, still suggesting that autophagy inhibitors could be combined to chemotherapies or immunotherapies (28).”
Tumor Microenvironment: No Effector T Cells without Dendritic Cells
Pfirschke, C., Siwicki, M. R., Liao, H.-W., & Pittet, M. J. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.007 · Cited by 60
Marsh, T., & Debnath, J. (2014) · Nature Cell Biology · doi:10.1038/ncb3089 · Cited by 35 · cited 2×
“Vps34 forms two distinct complexes involved either in the initiation of auto-phagy by interaction with Vps15/Atg14/UVRAG/Beclin1 or in the process of endocytosis where it interacts with Vps15/UVRAG/Rab5/ EEA1 ( 13 ).”
Sikorski, K., Wesoły, J., & Bluyssen, H. A. R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150814313 · Cited by 29 · cited 1×
“Many genes encoding the inflammatory signature, including CCL5 and CXCL10, are STAT1 targets (19).”
Blocking tumor growth by targeting autophagy and SQSTM1 in vivo
Wei, H., & Guan, J. (2015) · Autophagy · doi:10.1080/15548627.2015.1048173 · Cited by 21 · cited 1×
“However, the role of targeting autophagy on the inhibition of tumor growth and the infiltration of cytotoxic immune cells is well supported by several studies ( 8 , 9 , 14 , 23 – 25 , 27 , 29 ).”
Xiao, M., Noman, M. Z., Ménard, L., Chevigné, A., Szpakowska, M., Bosseler, M., Ollert, M. W., Berchem, G., & Janji, B. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018027526 · Cited by 6
Self-citation
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationAutophagy and autophagy-related pathways in cancer
Debnath, J., Gammoh, N., & Ryan, K. M. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00585-z · Cited by 1,403
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
“Vps34 inhibitor SB02024 or SAR405 results in elevated levels of CCL5, IFNγ, and other chemokines in TME, causing high levels of NK cells and T cells infiltration in myeloma and colorectal cancer models.(411) Furthermore, in an osteosarcoma model, tumor immunogenicity promoted by photodynamic therapy can be counteracte…”
BackgroundSelf-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Metadata
- Authors
- Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., Amaravadi, R. K., Martinsson, J., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Karolinska Institutet (SE)
- Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
- Sprint Bioscience (Sweden) (SE)
- Sprint Bioscience, Stockholm, Sweden.
- Abramson Cancer Center (US)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Berchem, Guy
- Janji, Bassam
- ORCID
- Venue
- Science Advances
- Published
- 2020-05
- Volume
- 6
- Issue
- 18
- Pages
- eaax7881-eaax7881
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7190323
- OpenAlex
- W3021675475
- Cited by
- 255
- References
- 40
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 51 · 2023: 46 · 2022: 55 · 2021: 39 · 2020: 15
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Luxembourg National Research Fund (C18/BM/12670304/COMBATIC)
- FNRS Televie (7.4664.15; 7.6503.16; 7.4606.18)
- Fondation Cancer, Luxembourg (FC/2016/01 and FC/2018/06)
- Kriibskrank Kanner Foundation Luxembourg (2016-08-15)
- Janssen Cilag Pharma
- Action LIONS Vaincre le Cancer, Luxembourg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- tumor immune microenvironment, PD-1/PD-L1 blockade, melanoma, colorectal cancer, T cell infiltration, RANTES, CXCL10, interferon-gamma, STAT1, IRF7, inflammatory chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.